Previously, a surgical regression model identified microRNA-101b (miR101b) as a potential inhibitor of cardiac hypertrophy. Here, we investigated the antihypertrophic mechanism of miR-101b using neonatal rat ventricular myocytes. miR-101b markedly suppressed agonist-induced cardiac hypertrophy as shown by cell size and fetal gene expression. By systems biology approaches, we identified protein kinase C epsilon (PKCe) as the major target of miR-101b. Our results from qRT-PCR, western blot, and luciferase reporter assays confirm that PKCe is a direct target of miR-101b. In addition, we found that effectors downstream of PKCe (p-AKT, p-ERK1/2, p-NFAT, and p-GSK3b) are also affected by miR-101b. Our study reveals a novel inhibitory mechanism for miR-101b as a negative regulator of cardiac hypertrophy.
Myocardial hypertrophy is an outcome of myocardium remodeling due to enlargement of cardiomyocytes in response to various pathological stimuli (e.g., hypertension, valvular disease, and myocardial infarction) [1, 2] . Although cardiac hypertrophy in its initial stage is considered as a compensatory response, it often proceeds to heart failure when hypertrophic stimuli persist. Hence, the cellular and molecular mechanisms underlying the hypertrophic processes have been intensively investigated over the past three decades.
Protein kinase C (PKC) is a group of serine/threonine protein kinases that can be activated by phospholipase C and phosphoinositides [3, 4] . PKC family members phosphorylate a variety of protein targets, and are known to be implicated in various cellular functions, including cell proliferation, survival, and programmed cell death [5, 6] . In particular, many studies have suggested that PKCs are associated with cardiac symptoms (i.e., myocardial hypertrophy, myocardial infarction, and heart failure). Indeed, Abbreviations b-MHC, beta-myosin heavy chain; ANF, atrial natriuretic factor; AngII, angiotensin II; BNP, brain natriuretic peptide; ET-1, endothelin-1; HEK, human embryonic kidney; IGF-1, insulin-like growth factor 1; ISO, isoproterenol; NFAT, nuclear factor of activated T cells; NRVMs, neonatal rat ventricular myocytes; PE, phenylephrine; PKC, protein kinase C; qRT-PCR, quantitative reverse transcription-PCR; TAC, transverse aorta constriction; UTR, untranslated region.
PKCs have been reported to play critical isoform-specific roles during the development of myocardial hypertrophy and heart failure [7, 8] . Among the 12 isoforms of PKC in the heart, PKCe is involved in signaling mechanisms such as proliferation, differentiation, and metabolism. Malfunctions in these processes are associated with heart symptoms such as ischemia/reperfusion injury, myocardial hypertrophy, and heart failure [9, 10] .
MicroRNAs (miRNAs) are endogenous small noncoding RNAs that negatively regulate gene expression post-transcriptionally by promoting mRNA degradation and inhibiting protein translations [11] . Recently, miRNAs have been reported to play key roles in the pathogenesis of cardiac diseases such as myocardial infarction, cardiac arrhythmias, and heart failure [12] . Notably, miRNA expression profiling studies have demonstrated that specific miRNAs participate in the course of pathological cardiac hypertrophy [13, 14] . Using a surgical model for regression of cardiac hypertrophy, we previously isolated miRNAs that negatively regulate cardiac hypertrophy. Among them, miR-101b was selected for further study here [15] .
In this study, we elucidated the antihypertrophic role of miR-101b in neonatal rat ventricular myocytes (NRVMs) using various hypertrophic agonists, and further demonstrated that PKCe is a novel target of miR101b. Negative regulation of the prohypertrophic signaling pathways downstream from PKCe was found to be associated with miR-101b. Our present study suggests that miR-101b is a potential therapeutic candidate for the treatment of cardiac diseases such as heart failure.
Materials and methods

Animal models
All animal experiments were approved by the Animal Care Committee of Gwangju Institute of Science and Technology (Approval number: GIST 2012-15), and were performed according to the guidelines from the GIST IACUC, and the NIH principles for the Care and Use of Laboratory Animals. All efforts were made to minimize suffering.
Cell culture
Neonatal rat ventricular myocytes were obtained from 1-to 2-day-old Sprague-Dawley rats as described previously [16] . In brief, ventricular tissue was enzymatically dissociated using collagenase (Collagenase type II; GIBCO, Grand Island, NY, USA), and the resulting cell suspension was enriched for cardiomyocytes using step gradients of Percoll (GE Healthcare, Piscataway, NJ, USA). Culture dishes or coverslips were precoated with 1% gelatin overnight and then cells were seeded in cardiomyocyte culture medium: DMEM supplemented with 10% fetal bovine serum, 1% antibiotics cocktail, 2 mM L-glutamine, and 100 lM 5-bromodeoxyuridine (BrdU; GIBCO-BRL, Gaithersburg, MD, USA). The cells were incubated at 37°C with 5% CO 2 .
Transfection of miRNA and hypertrophic stimulation miRIDIAN microRNA mimic rno-miR-101b, miRIDIAN microRNA mimic negative control #1 (NC), miRIDIAN microRNA hairpin inhibitor rno-miR-101b, and miRIDIAN microRNA hairpin inhibitor negative control #2 (NC inhibitor) were purchased from Dharmacon (Lafayette, CO, USA). NRVMs were cultured in serum-free medium for 24 h, and transfected with miRNA control, mimics, or antagomir using DharmaFECT-1, according to the manufacturer's protocol (Dharmacon). After 48 h, NRVMs were treated with each hypertrophic agonist for 24 h to induce hypertrophy. The agonists used were 100 lM phenylephrine (PE), 10 nM endothelin-1 (ET-1), 10 nM angiotensin II (AngII), or 10 lM isoproterenol (ISO).
Immunostaining and cell size measurement
Neonatal rat ventricular myocytes grown on gelatin-coated cover slips were fixed with 4% paraformaldehyde for 10 min, permeabilized with DPBS containing 0.5% Triton X-100 for 10 min, and blocked by incubation in a 5% BSA solution for 1 h. The cells were incubated with anti-a-actinin antibody (Sigma-Aldrich, St Louis, MO, USA) diluted 1 : 200 at 4°C overnight. A secondary antibody, AlexaFluor 594-coupled anti-mouse antibody (Invitrogen, Carlsbad, CA, USA) was added at a 1 : 200 dilution and incubated for 1 h at room temperature (25°C). Immunofluorescence was analyzed using an Olympus microscope (BX41, Olympus, Tokyo, Japan) with a 409 objective lens and filters for epifluorescence. Cell surface areas were measured using NIH IMAGEJ software (National Institutes of Health, Bethesda, MD, USA).
Quantitative real-time PCR (qRT-PCR)
TRI reagent (Sigma-Aldrich) was used for total RNA extraction from NRVMs. To examine expressional levels of cardiac hypertrophy marker genes, reverse transcriptase reactions were performed using ImProm II reverse transcriptase (Promega, Madison, WI, USA) with oligo-dT priming. qRT-PCR was performed using a Step One Plus real-time PCR system (Applied Biosystems, Foster City, CA, USA) with SYBR Green (Kapa Biosystems, Boston, MA, USA) as the fluorescent dyes. The primer sequences are shown in Table S2 .
Silencing protein expression by siRNA transfection
NRVMs were transfected with 50 nM siRNAs using DharmaFECT-1 reagent according to the manufacturer's instructions. The sense sequences of the siRNAs used were shown in Table S2 . Protein expression was measured by western blotting 48 h after transfection.
Western blot analysis
Protein samples were prepared from NRVMS using 1% SDS lysis buffer supplemented with protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany) and phosphatase inhibitor cocktail (Roche Dignostics). Protein samples were separated by SDS/PAGE and transferred to PVDF membranes (Millipore, Billerica, MA, USA), followed by blocking with 5% BSA (Sigma-Aldrich) in TBST (0.1% Tween-20 in Tris-buffered saline: 137 mM NaCl and 20 mM Tris/HCl, pH 7.4) for 1 h at room temperature. In case of NFAT, 8% skim milk (Difco, Detroit, MI, USA) in TBST was used for blocking. Membranes were then incubated overnight at 4°C with the following antibodies: PKCe (Cell Signaling Technology, MA, USA), phosphorylated-NFATc4 (p-NFATc4), NTAFc4, a-tubulin, and brain natriuretic peptide (BNP; Santa Cruz Biotechnology, Santa Cruz, CA, USA), atrial natriuretic factor (ANF) (Meridian Life Science, Memphis, TN, USA), beta-myosin heavy chain (b-MHC; Abcam, Cambridge, MA, USA), p-AKT, AKT, p-GSK3b, GSK3b, p-ERK1/2, and ERK1/2 (Cell Signaling Technology). Next, the membranes were incubated with the appropriate HRP-conjugated secondary antibody (AbFrontier, Seoul, Korea) at room temperature for 1 h, and luminescence was detected by using an ImageQuant LAS 4000 mini (GE Healthcare) and a SuperSignal West Pico Chemiluminescence Kit (Thermo Fisher Scientific, Waltham, MA, USA). The intensity of each protein band was quantified by NIH IMAGEJ software.
Luciferase reporter assay
For target gene validation, we constructed a reporter vector containing the 3 0 untranslated region (UTR) of the target gene. A luciferase assay was performed using the Dual-GLO luciferase assay system (Promega) according to the manufacturer's instructions. Briefly, we seeded human embryonic kidney (HEK-293) cells into a 12-well plate, and cotransfected the cells with 1.5 lg of pmiR-GLO plasmid and 20 nM or 50 nM miRNA mimics. After further cultivation for 72 h, cells were harvested and the luciferase activities were measured using a Victor3 luminometer (PerkinElmer Life and Analytical Sciences, Waltham, MA, USA). Relative luciferase activities were calculated as the ratio of firefly to Renilla luciferase activity. For measuring NFAT activity, NFATluciferase assays were performed as previously described with minor modifications [17] . Briefly, 9xNFAT-luciferase reporter plasmid and pRL-TK containing the Renilla luciferase gene were cotransfected into NRVMs with 20 nM miRNA mimics. After 24 h, to induce hypertrophy, cells were stimulated with 10 nM ET-1 for 24 h. A luciferase reporter plasmid driven by 9xNFAT binding sites was kindly provided by Dr. Jeffery D. Molkentin (University of Cincinnati).
Statistical analysis
All data are reported as the mean AE SD. Statistical significance was analyzed by using a two-way analysis of variance (ANOVA) with a Bonferroni post hoc analysis for multiple comparisons with PRISM 6.0 (GraphPad Software, Inc., San Diego, CA, USA). In all cases, P < 0.05 was considered statistically significant.
Results
miR-101b attenuated hypertrophic responses in agonist-treated NRVMs
To determine whether miR-101b could inhibit myocardial hypertrophy, NRVMs were cultured for 24 h with negative control-miRNA (NC-miR) or miR-101b mimics (20 nM each). NRVMs were then further treated for 24 h with each agonist to induce myocardial hypertrophy (10 nM ET-1, 100 nM PE, 10 nM AngII, or 10 lM ISO). The hypertrophic responses of NRVMs to the agonists were examined by measuring cell size, sarcomeric rearrangement, and the expression levels of hypertrophic markers (ANF, BNP, and b-MHC).
Immunostaining with a-actinin antibody (Fig. 1A ,B) revealed significantly larger cells with sarcomeric rearrangement in the agonists-treated NRVM group (with NC-miR pretreatment) compared to that in the control NRVM group (with NC-miR pretreatment). However, pretreatment with miR-101b mimics abolished the hypertrophic responses shown in the agonist-treated cells (Fig. 1A,B) . From the qRT-PCR data shown in Fig. 1C , the expression levels of hypertrophic markers such as ANF, BNP, and b-MHC were all elevated in the agonist-treated cells (with NC-miR pretreatment), but the elevations were substantially reduced in the presence of miR-101b mimics (Fig. 1C) . The protein expression levels of ANF, BNP, and b-MHC were also significantly reduced by miR-101b ( Fig. 1D ,E), suggesting that miR-101b plays an antihypertrophic role in NRVMs.
Systems biological approaches to identify the target gene of miR-101b
To identify the major target gene(s) of antihypertrophic miR-101b in NRVMs, we first performed computational miRNA target prediction using TARGETSCAN software [18] (Fig. S2 ). As shown in Fig. S2 , 8771 genes were initially identified as target genes for miR-101b. Among the 8771 genes, 805 genes with conserved sites between different species for miR101b were considered. Then, 598 genes expressed in the heart were selected using deep RNA-sequencing data [19] . From the 598 cardiac expressing genes, only 34 hypertrophy-associated genes were selected using pathway databases (Fig. S2) . Then, we selected only eight antihypertrophic genes through literature search [20] [21] [22] [23] . To study the selected miR-101b target gene candidates, NRVMs were transfected with either NCmiR or miR-101b, and the expression levels of mRNAs for the eight candidate genes were examined (Fig. S3) . The results showed that the level of PKCe mRNA was the only mRNA significantly inhibited by miR-101b, suggesting that PKCe is a target gene for miR-101b in the heart.
miR-101b directly targeted PKCe mRNA
The seed sequences in the PKCe 3 0 UTR targeted by miR-101b are highly conserved among the species such as human, mouse, and rat ( Fig. 2A) . To verify that PKCe is a direct target of miR-101b, NRVMs were cotransfected with a dual-luciferase reporter vector containing the PKCe wild-type 3 0 -UTR (WT-3 0 UTR) or mutated PKCe 3 0 -UTR (mut-3 0 UTR) downstream from the luciferase coding sequence. miR-101b mimics at 20 and 50 nM decreased the luciferase activity of WT-3 0 UTR by 31% and 59%, respectively. However, the effect of inhibition by 20 or 50 nM miR-101b mimics on luciferase activity was not observed in the mut- The expression levels were estimated by measuring band densities using the NIH IMAGEJ software. a-tubulin was used as a loading control. Data are expressed as fold changes AESD vs. the control group. Significance was measured via a two-way ANOVA. *P < 0.05. NC-miR, negative control-miRNA; ET-1, endothelin-1; PE, phenylephrine; AngII, angiotensin II; ISO, isoproterenol; Ctrl, control.
construct (Fig. 2B) . qRT-PCR and western blot analysis (Fig. 2C,D) further confirmed that PKCe expression was significantly decreased in NRVMs transfected with miR-101b mimics at both mRNA and protein levels (17% and 36% decrease, respectively). The inhibitory effect of miR-101b on PKCe protein expression is also clearly seen in the presence of 10 nM ET-1.
miR-101b inhibited PKCe signaling molecules in ET-1-induced hypertrophic cardiomyocytes
The PKCe prohypertrophic pathway induces cardiac hypertrophy through downstream mediators such as protein kinase B (AKT), glycogen synthase kinase3b (GSK3b), extracellular signal-regulated kinases (ERK1/2), and NFAT [24] . In light of this, western blot analysis was performed with antibodies detecting phosphorylated forms of the signaling molecules. The results showed that phosphorylation of AKT, GSK3b, and ERK1/2 was significantly elevated in ET-1-treated NRVMs (by 3.1-folds for AKT; 1.3-folds for GSK3b; and 1.4-folds for ERK1/2). However, the increased phosphorylation was prevented by pretreatment with miR-101b (Fig. 3A,B) . On the contrary, p-NFATc4, an inactive form, was significantly decreased in ET-1-treated NRVMs, while the phosphorylation levels were restored to the normal values by pretreatment with miR-101b mimic (Fig. 3A,B) . In addition, the NFAT-luciferase reporter assay showed that NFAT promoter activity was upregulated by 2.1-fold in ET-1-treated NRVM vs. control, but pretreatment with miR-101b decreased the activity both in control and ET-1 treatment groups (Fig. 3C) , suggesting that miR-101b substantially inhibits the PKCe signaling cascade during myocardial hypertrophy. 
Antagomir of miR-101b exacerbates ET-1-induced hypertrophic responses
The inhibitory role of miR-101b in cardiac hypertrophy was further tested by transfecting an antagomir of miR-101b into NRVMs. As expected, the hypertrophic responses (enlarged cell size, elevated mRNA expression of ANF, BNP, and b-MHC, and elevated protein expression of ANF, BNP, and b-MHC) were more intense in miR-101b antagomir transfected and ET-1-treated NRVMs compared to those in NC-miRtransfected and ET-1-treated NRVMs (Fig. 4A-E) . Notably, the hypertrophic responses were significantly elevated in miR-101b antagomir-treated NRVMs without ET-1 treatment (Fig. 4A-E) , further supporting the antihypertrophic role of miR-101b. Hypertrophic responses induced by inhibition of endogenous miR-101b were blocked by PKCespecific siRNA
To verify that the antihypertrophic role of miR-101b in NRVMs is through suppression of the PKCe signaling cascade, NRVMs were cotransfected with PKCe siRNA and miR-101b antagomir. Fifty nanomolar miR-101b antagomir was used to inhibit endogenous miR-101b, resulting in increased PKCe expression ( Fig. S4C-E) . Transfection of 50 nM siRNA for PKCe markedly decreased hypertrophic responses induced by miR-101b-silencing, as indicated by the enlarged cell were estimated by measuring band densities using the NIH IMAGEJ software. a-tubulin was used as a loading control. Data are expressed as fold change AESD vs. the control group. Significance was measured by a two-way ANOVA. *P < 0.05. NC-i, negative control-miRNA for antagomir; ET-1, endothelin-1; Ctrl, control; anti-miR-101b, antagomir of miR-101b.
size and increased expression of ANF and BNP (Fig. 5) . qRT-PCR results also showed that 50 nM siRNA for PKCe could inhibit the increased PKCe expression in the presence of miR-101b antagomir (Fig. S4E) . We also examined the effect of cotransfection of miR-101b and PKCe siRNA (50 nM each) into NRVMs. The results showed that the antihypertrophic effects (decreased surface area/expression levels of hypertrophy markers) of miR-101b were similar to the ones of coexpressed miR-101b and PKCe siRNA (Fig. 5) , suggesting that PKCe is the direct target of miR-101b.
miR-101b was downregulated during the process of cardiac hypertrophy by TAC
We performed qRT-PCR to examine the expression levels of miR-101b in mouse heart after the transverse The expression levels of the hypertrophy marker proteins shown in (E) were estimated by measuring the band densities using the NIH IMAGEJ software. aTubulin was used as a loading control. Data are expressed as fold changes AESD vs. control group. Significance was measured by a twoway ANOVA. *P < 0.05. NC-i, negative control-miRNA for antagomir; anti-miR-101b, antagomir of miR-101b; si-NC, negative control-siRNA; si-PKCe, PKCe siRNA.
aortic constriction (TAC) operation (Fig. S1 ). The miR-101b level did not significantly change until 2 weeks, but decreased in the period between 5 and 7 weeks significantly after TAC, suggesting that miR101b plays a prohypertrophic role during the later phase of cardiac hypertrophy.
Discussion
Cardiac hypertrophy is a major risk factor for cardiovascular morbidity and mortality [25, 26] . Although the disorder is initially a compensatory mechanism for mechanical loading, sustained cardiac hypertrophy eventually leads to cardiac dysfunction and heart failure [27] . Hence, there have been intensive efforts to discover the negative regulators of cardiac hypertrophy. In the past decade, miRNAs involved in various cardiovascular diseases have been reported in numerous in vitro and in vivo studies [28] . Some miRNAs have been reported to be prohypertrophic, while a smaller number of miRNAs are known to be antihypertrophic [28] . For example, miR-133 can be considered as an antihypertrophic miRNA, as mice overexpressing miR-133 showed reduced cardiac hypertrophy and improved cardiac functioning [29] . Conversely, inhibition of miR-133 caused severe cardiac hypertrophy, possibly due to targeting of RhoA and Cdc42 [30] . Our recent study also showed that miR-185 is antihypertrophic, due to its inhibition of cardiac hypertrophy by targeting Ca 2+ -signaling proteins such as Camk2d, Ncx1, and Nfatc3 [31] .
Previously, using a surgical model, we identified cardiac hypertrophy regression-specific miRNAs (miR101b, miR-142-3p, miR-181d, miR-24-2*, and miR450a) exhibiting antihypertrophic properties [16] . Among them, the cardio-protective role of miR-101b was of particular interest, as miR-101b showed the characteristics of negative regulator of cardiac hypertrophy. miR-101a or -101b is known as a negative regulator of myocardial infarction owing to its inhibition of cardiac fibrosis. Adenovirus-mediated overexpression of miR-101a or -101b diminished interstitial fibrosis and improved cardiac performance in infarcted rat hearts [32] . Collectively, the different pieces of evidence suggest that miR-101b plays a dual role in inhibition of both cardiac fibrosis and cardiac hypertrophy.
Data shown in Fig. S1A demonstrate the significantly decreased expression of miR-101b in the later stage of TAC (after 2 weeks), suggesting that the decreased cardio-protective miR-101b expression during TAC can accelerate hypertrophic, and possibly heart failure symptoms. The opposite effect, namely the abruptly increased expression of miR-101b, is caused by surgical removal of TAC [15] . Therefore, the study of the inhibitory role of miR-101b in cardiac hypertrophy is important to elucidate the pathogenesis of heart failure. Data shown in Fig. S1C -E demonstrate that expression of PKCe was increased at both transcriptional and translational levels during the compensatory hypertrophic period (e.g., TAC-2 weeks), consistent with our hypothesis. However, prolonged TAC (e.g., 5 weeks) led to diminished expression of miR-101b as well as PKCe (data not shown), where myocardial apoptosis, dilatation of myocardium, and functional abnormalities are apparent [1, 2] , suggesting that the miRNA regulation of cardiac hypertrophy is severely disturbed in the later stage of pressure overload hypertrophy.
Previous studies have shown that transgenic (TG) mice overexpressing PKCe demonstrate hypertrophic responses [33] , while overexpression of dominant negative PKCe can inhibit hypertrophic responses [34, 35] . PKCe-specific chemical inhibitor have been reported to block heart failure [23] , suggesting that PKCe plays a pivotal role in cardiac hypertrophy and heart failure. A recent study has shown that the hypertrophic effects of PKCe in the heart are associated with the activation of the AKT and ERK pathways [34, 36] , and suppression of AKT can attenuate the progress of cardiac hypertrophy [37, 38] . Consequently, activated AKT suppresses GSK3b, the negative regulator of cardiac hypertrophy, and activates NFAT transcriptional factor by dephosphorylation (see Fig. 6 ). In turn, activated AKT-mediated signaling, including via GSK3b and NFAT, contributes to the induction of cardiac hypertrophy. Indeed, AKT is a potential regulator of both physiological and pathological hypertrophy. AKT-overexpressing TG mice showed that short-term AKT activation induced physiological hypertrophy, whereas prolonged AKT activation resulted in pathological hypertrophy [39] . PKCe is known to activate ERK1/2 through phosphorylation. Here, we demonstrated experimentally that the protective role of miR-101b against cardiac hypertrophy is associated with activation of the signaling pathways involving PKCe/AKT/GSK3b/NFAT and ERK1/2. The antihypertrophic role of miR-101b through inhibition of PKCe signaling was further confirmed using an antagomir against miR-101b-and siRNA-targeted PKCe.
In the present study, we used NRVMs having multiple advantages in transfection efficiency, stability, and reproducibility. The novel findings of this study are: (a) miR-101b inhibited the hypertrophic responses in the agonist-treated hypertrophic NRVMs (Fig. 1) , (b) PKCe was identified as the major target gene for miR101b using the systems biological approaches (Fig. S2) , (c) miR-101b directly targeted PKCe mRNA at the conserved sites (Fig. 2) , (d) miR-101b inhibited myocardial hypertrophy through downregulation of essential proteins in the PKCe signaling pathway (Figs 3 and 6) , and (e) siRNA experiments (Fig. 5) verified that PKCe was the main target of miR-101b.
In conclusion, this study shows that miR-101b can alleviate the cardiac hypertrophy by regulating the PKCe signaling pathway (Fig. 6) . Exploiting the biology of miR-101b is a potential strategy for the prevention and treatment of important heart diseases. 
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